ClinicalTrials.gg
CompletedNCT02226965Updated Jun 29, 2023Results posted

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

A Phase 2 interventional study of PNT2258 in Lymphoma, Diffuse Large B-Cell, sponsored by Sierra Oncology LLC - a GSK company. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
403rd of 963
45 · median 37
Started
2014
with 27 others
Phase 2
380 of 1,131
47 open now
Registered
684th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 403rd largest by enrollment of the 963 interventional ones that give a count, is one of 28 that started in 2014, is one of 380 in phase 2, and was the 684th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.

03

Conditions studied

  • Lymphoma, Diffuse Large B-Cell

Keywords

  • PNT2258
  • DLBCL
  • Diffuse Large B-cell Lymphoma
  • NHL
  • Non-Hodgkin's Lymphoma
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

confirmed diffuse large B-cell lymphoma that is to prior therapy or relapsed after prior therapy.

FDG PET-CT (disease) positive baseline scan with .

The patient must have received prior therapy that included:

  • CD20-targeted therapy (for example, rituximab),
  • Alkylating agent (for example, cyclophosphomide), and
  • , unless the patient is steroid intolerant

Exposure to at least 1 or 2 (but no more than 3) prior systemic cytotoxic chemotherapeutic regimens.

Note: Only those subjects who are not eligible for high-dose chemotherapy and stem cell transplant (HD-ASCT), or who refuse HD-ASCT, are eligible with exposure to only 1 prior cytotoxic chemotherapeutic regimen.

performance status of 0-1.

The patient must be a stable baseline with grade ≤ 2 regarding any acute or chronic toxicity associated with prior therapy, and have discontinued prior anti-cancer therapy for ≥ 14 days prior to C1D1; mitomycin-C for at least 6 weeks prior to C1D1; SCT ≥ 2 months prior to C1D1.

Note: Palliative steroids for control of disease-related symptoms are allowed and maintenance hormone therapy is allowed.

Adequate organ function including:

  • Hematologic: ≥ 0.5 x 10\^9/L. and ≥ 50 x 10\^9/L.
  • Hepatic: Total ≤ 2 x (patients with Gilbert's syndrome must have total bilirubin ≤ 3 x ULN) and serum transaminase levels ≤ 2.5 x ULN. In the case of known liver (i.e., radiological or documented), serum transaminase levels must be ≤ 5 x ULN.
  • Renal: Serum creatinine ≤ 2 x ULN, or ≥ 60 mL/min/1.73 m2 for subjects with serum creatinine levels above 2 x ULN.

Willingness to: 1.) undergo pre-treatment biopsy to obtain adequate tissue for analysis (e.g., core needle, excisional or incisional tumor biopsy) or 2.) provide archived tumor (e.g., FFPE block) for analysis.

Exclusion criteria

Exclusion Criteria:

Eligibility for high-dose chemotherapy (HDT) and stem cell transplant (SCT). Note: Subjects who progressed ≥ 2 months after HDT/SCT are eligible

Concurrent requiring treatment.

Primary mediastinal (thymic) large B-cell lymphoma

Symptomatic CNS or of lymphoma.

Concurrent illness, medical condition, surgical history, physical finding, or laboratory finding that, in the opinion of the investigator, could adversely affect the safety of the patient or impair the assessment of the study results.

Signs or symptoms of heart failure characterized as greater than Class II or other significant cardiac abnormalities.

Pregnant or breast-feeding.

Prior exposure to PNT2258.

less than 3 months.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    PNT2258

    PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 "induction" cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258.

    Drug: PNT2258

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    The proportion of patients with complete response (CR/complete metabolic response \[CMR\]) or partial response (PR/partial metabolic response \[PMR\]) according to the revised 2014 International Working Group (IWG) criteria for lymphoma (Cheson 2014)

    Time frame: 19 months

Secondary outcomes

  1. Disease Control Rate

    The proportion of patients who have a response of stable disease (SD/no metabolic response \[NMR\]) or better by investigator assessment

    Time frame: 19 months

  2. Time to Response

    The number of months from Cycle 1 Day 1 until the date of the first documented response

    Time frame: 19 months

  3. Progression-free Survival

    The number of months from C1D1 until the date of DLBCL progression or death from any cause, or to the last date at which progression status was adequately assessed for censored observation

    Time frame: 19 months

  4. Safety - Assessment of Adverse Events

    Characterization of the type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events, laboratory abnormalities, serious adverse events or adverse events leading to discontinuation of study treatment

    Time frame: 36 months

  5. Overall Survival

    The number of months from C1D1 until the date of death from any cause, or to the last date at which survival status was adequately assessed for censored observations

    Time frame: 19 months

  6. Duration of Overall Response

    The time from the initial CMR or PMR until the date of progression or death from any cause, or to the last date at which progression status was adequately assessed for censored observations

    Time frame: 19 months

07

Results

Posted Apr 22, 2020

Participant flow

The study was initiated in December 2014 and the first subject was enrolled on 10 December 2014. A total of 60 subjects were screened. Enrollment was closed as of 07 June 2016. Subjects were enrolled at oncology clinics in the USA.

Participant flow — Overall Study
MilestonePNT2258
Started45
Completed4
Not completed41

Outcome measures

PrimaryOverall Response Rate

The proportion of patients with complete response (CR/complete metabolic response \[CMR\]) or partial response (PR/partial metabolic response \[PMR\]) according to the revised 2014 International Working Group (IWG) criteria for lymphoma (Cheson 2014)

Time frame:
19 months
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPNT2258
Overall Response Rate11.1 (3.7 to 24.1)
SecondaryDisease Control Rate

The proportion of patients who have a response of stable disease (SD/no metabolic response \[NMR\]) or better by investigator assessment

Time frame:
19 months
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsPNT2258
Disease Control Rate20.0 (9.6 to 34.6)
SecondaryTime to Response

The number of months from Cycle 1 Day 1 until the date of the first documented response

Time frame:
19 months
Reported as:
Mean · months
Time to Response
monthsPNT2258
Time to Response2.2 (1.9 to 5.4)
SecondaryProgression-free Survival

The number of months from C1D1 until the date of DLBCL progression or death from any cause, or to the last date at which progression status was adequately assessed for censored observation

Time frame:
19 months
Reported as:
Median · months
Progression-free Survival
monthsPNT2258
Progression-free Survival1.9 (1.4 to 1.9)
SecondarySafety - Assessment of Adverse Events

Characterization of the type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events, laboratory abnormalities, serious adverse events or adverse events leading to discontinuation of study treatment

Time frame:
36 months
Reported as:
Number · participants reporting at least 1 AE
Safety - Assessment of Adverse Events
participants reporting at least 1 AEPNT2258
Safety - Assessment of Adverse Events45
SecondaryOverall Survival

The number of months from C1D1 until the date of death from any cause, or to the last date at which survival status was adequately assessed for censored observations

Time frame:
19 months
Reported as:
Median · months
Overall Survival
monthsPNT2258
Overall Survival9.8 (0.3 to 19.1)
SecondaryDuration of Overall Response

The time from the initial CMR or PMR until the date of progression or death from any cause, or to the last date at which progression status was adequately assessed for censored observations

Time frame:
19 months
Reported as:
Median · months
Duration of Overall Response
monthsPNT2258
Duration of Overall Response5.3 (0.0 to 8.3)

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PNT225811/45 (24.4%)18/45 (40%)45/45 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPNT2258
PyrexiaGeneral disorders5/45
HypotensionVascular disorders3/45
Disease progressionGeneral disorders3/45
SepsisInfections and infestations3/45
PneumoniaInfections and infestations3/45
Abdominal painGastrointestinal disorders2/45
Failure to thriveMetabolism and nutrition disorders2/45
Respiratory failureRespiratory, thoracic and mediastinal disorders2/45
Tumor flareNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/45
Abdominal distensionGastrointestinal disorders1/45
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPNT2258
FatigueGeneral disorders20/45
NauseaGastrointestinal disorders18/45
DiarrhoeaGastrointestinal disorders18/45
PyrexiaGeneral disorders13/45
AnaemiaBlood and lymphatic system disorders13/45
VomitingGastrointestinal disorders11/45
Decreased appetiteMetabolism and nutrition disorders11/45
DizzinessNervous system disorders11/45
ThrombocytopeniaBlood and lymphatic system disorders11/45
Back PainMusculoskeletal and connective tissue disorders10/45

Baseline characteristics

All patients who passed the screening in the study

Age, Continuous
Age, Continuous(years)PNT2258
Median64 (26 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)PNT2258
Female29
Male16
08

Study locations

27 sites
  • Long Beach Memorial Medical Center
    Long Beach, California 90806, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Colorado Blood and Cancer Institute
    Denver, Colorado 80218, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Bond Clinic, P.A.
    Winter Haven, Florida 33880, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana 47905, United States
  • UHC Oncology
    Lafayette, Louisiana 70506, United States
  • Western Maryland Health System
    Cumberland, Maryland 21502, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Mercy Health Saint Mary's
    Grand Rapids, Michigan 49503, United States
  • St. John Hospital and Medical Center
    Grosse Pointe Woods, Michigan 48236, United States
  • Michigan State University
    Lansing, Michigan 48910, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Bon Secours Saint Francis Cancer Center
    Greenville, South Carolina 29607, United States
  • Avera Research Institute
    Sioux Falls, South Dakota 57108, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Tyler Hematology Oncology
    Tyler, Texas 75701, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • Medical Oncology Associates, PS
    Spokane, Washington 99208, United States
  • Fundacion de Investigacion
    San Juan, 00927, Puerto Rico
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jul 2016, 19 months.

Results were first posted in Apr 2020, 3 years 9 months after primary completion.

Of 53 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 19 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 27, 2014
StartActual
Dec 2014
Primary completionActual
Jul 11, 2016
CompletionActual
Aug 22, 2018
Results first posted
Apr 22, 2020
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02226965
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Dec 2014
Primary completion
Jul 11, 2016
Completion
Aug 22, 2018
Results posted
Apr 22, 2020
Last update
Jun 29, 2023

Study contacts

Barbara Klencke, MD
study chair · Sierra Oncology LLC - a GSK company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PNT100

Start the discussion